LoginJoin 2026 meeting Help pages

Pages In this section

Sheffield 2026 Presented e-posters Thursday


Screen 1

No ePosters found. Please select a year or use the search form

Screen 2

No ePosters found. Please select a year or use the search form

Screen 3


Click the “View PDF” button or the Image for a high quality PDF file.

Click BACK in browser to return after viewing PDF.


ePosters can only be viewed by delegates with a ticket or BOPSS members with a paid sibscription


Title Lacrimal Gland Biopsy: Diagnostic Yield and Safety Profile from a 14-Year Retrospective Audit in a Tertiary Referral Centre.
Number 322
Author Caoimhe Normile
Principal Unit where research was undertaken Royal Victoria Eye and Ear Hospital Dublin

Purpose Lacrimal gland enlargement presents a diagnostic challenge, with overlap in presentation between inflammatory and neoplastic disease. Biopsy is often required to exclude malignancy. This study evaluates the diagnostic yield and safety of lacrimal gland biopsy in a tertiary referral centre.
Methods A retrospective review of all lacrimal gland biopsies performed between 2010 and 2024 was conducted. Data collected included patient demographics, clinical features, imaging findings, histopathology, and outcomes including recurrence and post-operative complications.
Results Seventy-nine biopsies were analysed (mean age 49 years; 62% female). Inflammatory pathology was most common (44%); however, neoplastic disease accounted for 32% of cases. Lymphoma was identified in 19% (approximately 1 in 5 patients). Malignant tumours such as adenocarcinoma and metastases were less frequent (5%), pleomorphic adenomas accounted for 7.5% of cases, 12% of biopsies were benign cysts, and 10% of biopsies were normal. Post-operative complications were infrequent, with no vision-threatening events observed. Recurrence was uncommon (<10%).
Conclusion Lacrimal gland biopsy demonstrates a high diagnostic yield with a substantial risk of malignancy and a favourable safety profile. A low threshold for biopsy is supported, as the risk of missed malignancy outweighs procedural risk.

Additional Authors

First name Last name Hospital / Institution
Rizwana Khan



This page is in the following categories. Click category button to view other pages in same category.

BOPSS-Meeting 2026